PropThink: ENDP Validates That New Opana ER Formulation Reduces Abuse; Stock Should Respond Favorably
(Thomson Reuters ONE) -
By Jake King
Against a backdrop of growing opioid abuse in the U.S., Endo Health Solutions
(NASDAQ:ENDP) announced another step Monday night in its efforts to curb abuse
of its older, first generation pain management drug, Opana ER, and solidify
market dominance of its new abuse-resistant formulation, launched in mid-2012.
The company added a supplement to its existing Citizen Petition (CP) to the FDA,
including the results of a year-long study that, according to the company,
demonstrate, "abuse of the reformulated Opana ER was reduced by 59 percent,
based on the total number of prescriptions dispensed, versus the rate observed
for the non-tamper-resistant formulation of Opana ER, which is no longer being
manufactured by the company." Continue reading.
See the full story at PropThink.com.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1658021]
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2012 - 16:56 Uhr
Sprache: Deutsch
News-ID 203654
Anzahl Zeichen: 3039
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 151 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: ENDP Validates That New Opana ER Formulation Reduces Abuse; Stock Should Respond Favorably"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
